More studies are needed to investigate whether genes located at loci 13q, 21p and 22q could harbour potential new therapeutic targets and whether RB1 deficiency could be a predictive biomarker for hormone therapy response for patients with BC carrying one or two mutated copies of ATM. The gene discussed is ATM; the disease is breast cancer.